Chondroitin sulfate (1200
mg/day) has been shown to be
superior to celecoxib (200mg per
day) at reducing cartilage loss while
demonstrating similar efficacy at
reducing disease symptoms in
knee osteoarthritis (OA) patients,
according to a two-year doubleblind
randomised controlled
multi-centre study presented to the
American College of Rheumatology
Annual Meeting in San Francisco.
Lead author Professor Jean-
Pierre Pelletier director, Rheumatic
Disease Unit, University of
Montreal School of Medicine
cautioned that the study used
pharmaceutical-grade chondroitin
as opposed to food-supplement
chondroitin.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Nov 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.